Is Carbopladin a Part Inhibitor?

A 59 year old woman, healthcare worker, we started her on palbocyclib and leprosol and zolidronic acid for her bone metastases. But interestingly, she did have pal B2 alteration at a very high frequency. So that led to testing her genetics which showed pathogenic pal B2 mutation. A question that I have, can these patients with pal B1 mutation be considered for part inhibitors? How important is it to use carbopladin as part of the chemotherapy regimen? What investigators feel about the choice of CDK 46 inhibitor?